FIN 403

Drug Profile

FIN 403

Alternative Names: FIN-403

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Finch Therapeutics
  • Developer Finch Therapeutics Group
  • Class Bacteria; Probiotics
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Clostridium infections

Most Recent Events

  • 23 Oct 2017 Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group
  • 10 Mar 2017 FIN 403 is available for licensing as of 23 Feb 2017.
  • 02 Mar 2017 Finch Therapeutics completes a clinical trial in Clostridium infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top